Pulmonary embolism classification

Jump to navigation Jump to search

Pulmonary Embolism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pulmonary Embolism from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

Assessment of Clinical Probability and Risk Scores

Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores

History and Symptoms

Physical Examination

Laboratory Findings

Arterial Blood Gas Analysis

D-dimer

Biomarkers

Electrocardiogram

Chest X Ray

Ventilation/Perfusion Scan

Echocardiography

Compression Ultrasonography

CT

MRI

Treatment

Treatment approach

Medical Therapy

IVC Filter

Pulmonary Embolectomy

Pulmonary Thromboendarterectomy

Discharge Care and Long Term Treatment

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Follow-Up

Support group

Special Scenario

Pregnancy

Cancer

Trials

Landmark Trials

Case Studies

Case #1

Pulmonary embolism classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulmonary embolism classification

CDC on Pulmonary embolism classification

Pulmonary embolism classification in the news

Blogs on Pulmonary embolism classification

Directions to Hospitals Treating Pulmonary embolism classification

Risk calculators and risk factors for Pulmonary embolism classification

Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Pulmonary embolism is classified based on the nature of symptom presentation and the overall severity of disease. Symptom presentation is largely influenced by the time of appearance of symptoms and size of the embolus. Disease severity can be further stratified into three levels of risk: massive, submassive, and low-risk.

Classification Based on Temporality & Size

The classification of a pulmonary embolism is considerably influenced by the temporal manifestation and the overall physical size at presentation. Classification on this criteria is not mutually exclusive from disease severity. Thus, an acute or chronic embolus can be further classified into any of the categories of disease severity discussed further below.

Acute Pulmonary Embolism

A pulmonary embolism is classified as acute if it meets any of the following criteria:

  • Time Criterion: Symptoms onset and physical sign presentation occur immediately after obstruction of pulmonary vessels
  • Embolus Size Criteria:
  • Embolus is located centrally within the vascular lumen.
  • Embolus occludes a vessel.
  • Embolus causes distention of the involved vessel.

Chronic Pulmonary Embolism

A pulmonary embolism is classified as chronic if it meets any of the following criteria:

  • Embolus is eccentric and contiguous with the vessel wall.
  • Embolus reducing the arterial diameter by ≥50%.
  • Evidence of recanalization within the thrombus.
  • Presence of an arterial web.

Classification Based on Disease Severity

In addition to time of presentation and size of embolus, a pulmonary embolism can be additionally classified based on the severity of disease. Three major classifications exist: massive, submassive, and low-risk. The incidence of these severity levels are 5%, 40%, and 55%, respectively.

Massive Pulmonary Embolism

  • Historical classification: A massive pulmonary embolism was defined using the Miller Index of angiographic burden.[2] This is a retrospective diagnosis based upon the pulmonary angiogram that does not inform prospective decisions.
  • Contemporaneous classification: Recently, the American Heart Association has proposed the following definition for massive PE: An acute pulmonary embolism with:
  • Sustained hypotension (systolic blood pressure <90 mm Hg) for at least 15 minutes or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or left ventricular dysfunction
  • Pulselessness
  • Persistent profound bradycardia (heart rate <40 bpm with signs or symptoms of shock)[3]

Submassive Pulmonary Embolism

  • Submassive pulmonary embolism patients share the following characteristics:[4][5]
  • A significantly higher rate of in-hospital complications.
  • A higher potential for long-term pulmonary hypertension and cardiopulmonary disease.
  • Though patients with submassive pulmonary emboli may appear hemodynamically and clinically stable initially, there is potential to undergo a cycle of progressive right ventricular failure. A submassive pulmonary embolism requires continuous monitoring to prevent irreversible damage and death.[6]

Saddle Pulmonary Embolism

  • A saddle pulmonary embolism is classified as an embolus that lodges at the bifurcation of the main pulmonary artery into the right and left pulmonary arteries.
  • Saddle pulmonary embolisms are typically classified as submassive.

Low-risk Pulmonary Embolism

  • The American Heart Association defines a low-risk pulmonary embolism as an acute pulmonary embolism and the absence of clinical markers of adverse prognosis that define massive or submassive PE. [3]

References

  1. Castañer E, Gallardo X, Ballesteros E, Andreu M, Pallardó Y, Mata JM; et al. (2009). "CT diagnosis of chronic pulmonary thromboembolism". Radiographics. 29 (1): 31–50, discussion 50-3. PMID doi=10.1148/rg.291085061 19168835 doi=10.1148/rg.291085061 Check |pmid= value (help).
  2. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M (1971). "Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism". Br Heart J. 33 (4): 616. PMID 5557502.
  3. 3.0 3.1 3.2 Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ; et al. (2011). "Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association". Circulation. 123 (16): 1788–830. doi:10.1161/CIR.0b013e318214914f. PMID 21422387.
  4. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L (1999). "Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis". Circulation. 99 (10): 1325–30. PMID 10077516. Retrieved 2011-12-21. Unknown parameter |month= ignored (help)
  5. Fengler BT, Brady WJ (2009). "Fibrinolytic therapy in pulmonary embolism: an evidence-based treatment algorithm". Am J Emerg Med. 27 (1): 84–95. doi:10.1016/j.ajem.2007.10.021. PMID 19041539. Retrieved 2011-12-21. Unknown parameter |month= ignored (help)
  6. Cannon CP, Goldhaber SZ (1996). "Cardiovascular risk stratification of pulmonary embolism". Am. J. Cardiol. 78 (10): 1149–51. PMID 8914880. Retrieved 2011-12-21. Unknown parameter |month= ignored (help)

Template:WH Template:WS